Trial · NCT01349972
Adverse events156
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 156
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Febril eNeutropenia | Blood and lymphatic system disorders | Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride) | 5 | 114 | 5 |
| other | Febril eNeutropenia | Blood and lymphatic system disorders | Arm II (Cytarabine, Daunorubicin Hydrochloride) | 7 | 58 | 7 |
| other | Sepsis | Infections and infestations | Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride) | 4 | 114 | 4 |
| other | Sepsis | Infections and infestations | Arm II (Cytarabine, Daunorubicin Hydrochloride) | 1 | 58 | 1 |
| other | Catheter Related Infection | Infections and infestations | Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride) | 0 | 114 | 0 |
| other | Catheter Related Infection | Infections and infestations | Arm II (Cytarabine, Daunorubicin Hydrochloride) | 1 | 58 | 1 |
| other | Bacteremia | Infections and infestations | Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride) | 2 | 114 | 2 |
| other | Bacteremia | Infections and infestations | Arm II (Cytarabine, Daunorubicin Hydrochloride) | 0 | 58 | 0 |
| other | Pneumonia | Infections and infestations | Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride) | 0 | 114 | 0 |
| other | Pneumonia | Infections and infestations | Arm II (Cytarabine, Daunorubicin Hydrochloride) | 1 | 58 | 1 |
| other | Infectious Enterocolitis | Infections and infestations | Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride) | 2 | 114 | 2 |
| other | Infectious Enterocolitis | Infections and infestations | Arm II (Cytarabine, Daunorubicin Hydrochloride) | 0 | 58 | 0 |
| other | mucositis | Gastrointestinal disorders | Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride) | 1 | 114 | 1 |
| other | mucositis | Gastrointestinal disorders | Arm II (Cytarabine, Daunorubicin Hydrochloride) | 3 | 58 | 3 |
| other | Tumor Lysis Syndrome | Metabolism and nutrition disorders | Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride) | 1 | 114 | 1 |
| other | Tumor Lysis Syndrome | Metabolism and nutrition disorders | Arm II (Cytarabine, Daunorubicin Hydrochloride) | 3 | 58 | 3 |
| other | Hypokalemia | Investigations | Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride) | 1 | 114 | 1 |
| other | Hypokalemia | Investigations | Arm II (Cytarabine, Daunorubicin Hydrochloride) | 0 | 58 | 0 |
| other | Mypocardial Infarction | Cardiac disorders | Arm I (Alvocidib, Cytarabine, Mitoxantrone Hydrochloride) | 0 | 114 | 0 |
| other | Mypocardial Infarction | Cardiac disorders | Arm II (Cytarabine, Daunorubicin Hydrochloride) | 1 | 58 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01349972/events